Could this be the secret to Pfizer's rebound strategy?

Pfizer's business may be in better shape than investors think.

It could prove to be a case of better later than never for the healthcare giant.

Pfizer is struggling right now, leaving it in the Wall Street doghouse; it won't be there forever.

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Pfizer said on Thursday that finance chief Dave Denton will leave ⁠on August 15 to return to the consumer goods industry.

Futures are trading higher as we get ready to start the first full week of trading for the third quarter, as traders and ...

By Andrew Silver SHANGHAI, June 29 (Reuters) - GLP-1 drugs from Pfizer and Innovent Biologics have passed a preliminary ...

The sports apparel giant is turning to new financial leadership as it looks to make more progress with its “Win Now” ...